No Data
Hoth Therapeutics Launches Rocket One Space Subsidiary Initiative
Express News | Hoth Therapeutics Inc - No Treatment-Limiting Adverse Events Observed in Ht-001 Phase 2a Trial
Express News | Hoth Therapeutics Inc - No Patients Required Dose Reduction or Discontinuation of Egfr Inhibitor Therapy
Express News | Hoth Therapeutics Inc - Over 65% of Patients Reported Meaningful Reductions in Pain and Itching in Ht-001 Trial
Express News | Hoth Therapeutics Inc - Ht-001 Phase 2a Interim Data Show Primary Efficacy Endpoint Achieved by Week 6
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients